Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-12-20
2004-05-11
Huff, Sheela J. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S204100, C424S231100, C536S023100, C536S023500, C530S350000
Reexamination Certificate
active
06734167
ABSTRACT:
Applicants claim the benefit of the earlier filing date of Great Britain Application No. 9930519.5, filed Dec. 24, 1999, which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
This invention relates to uses of transport-active proteins, particularly of proteins and fusion polypeptides with the function of VP22, for control of the cell cycle, particularly in the reduction of the proliferating activity of proliferating cells.
BACKGROUND OF THE INVENTION AND PRIOR ART
The transport properties of VP22 and homologues thereof are described in WO 97/05265 (P O'Hare and G Elliott). WO 98/32866 (P O'Hare et al.) discusses coupled polypeptides and fusion polypeptides for intracellular transport, and their preparation and use. Intercellular trafficking and protein delivery by a herpesvirus structural protein is described in Cell (1997), Vol. 88, pp223-233 (G Elliott and P O'Hare).
The prior art generally includes a variety of cell cycle control proteins, especially in the forms of protein and polynucleotide sequences enabling genetic manipulation by standard techniques.
For example, among cell cycle control proteins, protein p53 is known as a tumor suppressor. p53 is a 53 kDa nuclear phosphoprotein. Wild type and mutant p53 proteins have been expressed by means of recombinant vaccinia viruses (Ronen et al., Nucleic Acids Research, 20, pp 3435-3441, 1992). p53 functions to regulate cell cycle progression and under conditions of DNA damage can induce cell cycle arrest or apoptosis through a complex signal transduction mechanism (Levine A. J. Cell, 88, pp323-331, 1997).
Other proteins known to promote cell death include the bax protein, and homologues such as the Bak protein, including its BH3 domain (E P Hollinger et al., 1999, J Biol. Chem., 274 (19), pp 13298-13304).
REFERENCES:
patent: 5747641 (1998-05-01), Frankel et al.
patent: WO 97/05265 (1997-02-01), None
patent: WO 98/32866 (1998-07-01), None
patent: WO 98/42742 (1998-10-01), None
Dalton et al, J. Clin. Oncol. vol. 7 p. 415 (1989).*
Fernandez et al. Nature Biotechnology vol. 16 p. 418 (1998).*
Murphy et al, Gene Therapy vol. 6 p. 4(1999).*
Orkin et al, report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (1995).*
Dilber et al.: “Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22”—Gene Therapy, 6(1):12-21, 1999.
Elliott and O'Hare: “Intercellular Trafficking of VP22-GFP fusion proteins,”Gene Therapy, 6, 149-151, 1999.
Brewis Neil Douglas
Normand Nadia Michelle
O'Hare Peter Francis Joseph
Phelan Anne
Huff Sheela J.
Klarquist & Sparkman, LLP
Phogen Limited
LandOfFree
Uses of transport proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of transport proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of transport proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3235492